Frequency Of Marrow Infiltrating Pd-1 Expressing Cd4 Effectors Following Autologous Stem Cell Transplant (Asct) For Multiple Myeloma Is Prognostic For Clinical Outcome

Introduction: High dose therapy and autologous stem cell transplant (ASCT) remain standard first line therapy for young fit patients with multiple myeloma (MM). Beyond cytoreduction, ASCT may also alter the bone marrow (BM) immune environment to augment anti-tumour immune responses. A more precise understanding of the immune microenvironment post ASCT and its relationship with clinical outcomes may identify biomarkers to refine prognostication and provide opportunity for therapeutic intervention.